Quick Answer
ENDRA Life Sciences Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
ENDRA Life Sciences Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $0.00 | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | -100.0% |
| 2021 | $546.6K | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $0.00 | -100.0% | — |
| December 31, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $281.2K | -40.5% | -13.2% |
| March 31, 2023 | $324.1K | -36.5% | -11.4% |
| December 31, 2022 | $365.9K | -33.1% | -15.7% |
| September 30, 2022 | $434.3K | — | -8.1% |
| June 30, 2022 | $472.7K | — | -7.3% |
| March 31, 2022 | $510.1K | — | -6.7% |
- Over the 2021–2024 period, ENDRA Life Sciences Inc.’s long-term debt has declined by 100.0% (from $546.6 thousand to $0.00).
- The most recent figure is from ENDRA Life Sciences Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: